Neoadjuvant Intralesional Methotrexate for Infiltrating Squamous Cell Carcinoma of the Head: A Case Series of 19 Patients.

IF 1.8 4区医学 Q2 DERMATOLOGY

Australasian Journal of Dermatology Pub Date : 2025-05-20 DOI:10.1111/ajd.14529

Caterina Mariarosaria Giorgio, Gaetano Licata, Eugenia Veronica Di Brizzi, Giulia Briatico, Elvira Moscarella, Camila Scharf, Maria Maddalena Nicoletti, Giuseppe Argenziano, Gabriella Brancaccio

引用次数: 0

Abstract

Squamous cell carcinoma (SCC) of the head presents a significant challenge in achieving complete surgical excision while preserving function and aesthetics. Neoadjuvant intralesional methotrexate (MTX) has emerged as a potential strategy to reduce tumour burden preoperatively, facilitating more conservative surgical excisions. The results demonstrated significant lesion shrinkage, with a mean tumour size reduction of 68%, enabling less invasive surgical interventions.

查看原文本刊更多论文

新辅助瘤内甲氨蝶呤治疗浸润性头部鳞状细胞癌19例。

头部鳞状细胞癌（SCC）在保持功能和美观的同时实现完全手术切除是一个重大挑战。新辅助病灶内甲氨蝶呤（MTX）已成为一种潜在的策略，以减少术前肿瘤负担，促进更保守的手术切除。结果显示病变显著缩小，平均肿瘤大小缩小68%，使微创手术干预成为可能。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Australasian Journal of Dermatology 医学-皮肤病学

CiteScore

3.20

自引率

5.00%

发文量

186

审稿时长

6-12 weeks

期刊介绍： Australasian Journal of Dermatology is the official journal of the Australasian College of Dermatologists and the New Zealand Dermatological Society, publishing peer-reviewed, original research articles, reviews and case reports dealing with all aspects of clinical practice and research in dermatology. Clinical presentations, medical and physical therapies and investigations, including dermatopathology and mycology, are covered. Short articles may be published under the headings ‘Signs, Syndromes and Diagnoses’, ‘Dermatopathology Presentation’, ‘Vignettes in Contact Dermatology’, ‘Surgery Corner’ or ‘Letters to the Editor’.